Hematopoietic Cell Transplantation for Testicular Cancer — CPB 0617 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0617 governing hematopoietic cell transplantation (HCT) for testicular cancer, effective December 5, 2025. Here's what changes for billing teams.

This update to the Aetna hematopoietic cell transplantation coverage policy draws a sharp line between covered autologous procedures and excluded allogeneic ones. CPT codes 38206–38230, 38241, and the full 96400-series chemotherapy administration codes are all in scope. If your oncology or transplant program bills Aetna for testicular cancer cases, audit your prior authorization workflows and clinical documentation before December 5, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Hematopoietic Cell Transplantation for Testicular Cancer
Policy Code	CPB 0617
Change Type	Modified
Effective Date	December 5, 2025
Impact Level	High
Specialties Affected	Oncology, Hematology, Transplant Surgery, Infusion/Chemotherapy
Key Action	Confirm all HCT claims for testicular cancer map to autologous procedures and meet the specific clinical criteria below before submitting under CPT 38241 or 38206–38230.

---

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The Aetna HCT coverage policy under CPB 0617 covers autologous hematopoietic cell transplantation for testicular cancer in three specific clinical scenarios. Each one has a distinct trigger. Document the correct one precisely — vague clinical notes will not support medical necessity on review.

Scenario 1: Refractory disease after initial standard-dose chemotherapy.
Aetna covers autologous HCT when a patient does not reach complete remission after a first course of standard-dose chemo. That means either refractory disease (less than 50% reduction in tumor burden) or a partial response (at least a 50% reduction, but not complete remission). These are different clinical thresholds. Make sure your documentation specifies which one applies.

Scenario 2: Relapse after initial standard-dose chemotherapy.
Autologous HCT as consolidation therapy is medically necessary when a patient relapses after that first chemotherapy course. This is a consolidation indication — not salvage, not first-line. The clinical record must show the prior chemo regimen and the relapse event.

Scenario 3: Tandem autologous HCT for relapsed disease.
Aetna also covers tandem autologous HCT — two sequential transplants — for patients who have relapsed. This is the most complex billing scenario. You're looking at multiple admissions, multiple stem cell collection and infusion codes, and a much longer authorization window to manage.

All three covered scenarios reference standard-dose chemotherapy as the prior treatment. The policy excludes autologous HCT as a replacement for an initial course of standard-dose chemotherapy with FDA-approved drugs. The covered criteria reference "standard-dose chemotherapy" without the FDA qualifier — but clinical teams should be aware of this language in the exclusion. If a patient's initial regimen included any investigational agents, that may create a coverage gap worth flagging with your medical director.

Prior authorization requirements are not specified in CPB 0617. Consult Aetna's administrative guidelines and your provider agreement to determine prior auth obligations for HCT procedures. A claim denial on a transplant case is not a routine write-off situation — reimbursement exposure on these cases is significant.

---

Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications

Two procedures are explicitly excluded under CPB 0617. Neither has a workaround.

First-line autologous HCT. Aetna will not cover autologous HCT as the initial treatment for testicular cancer — meaning instead of a first course of standard-dose, FDA-approved chemotherapy. The policy language is direct: HCT used before the patient has received standard-dose chemo is experimental, investigational, or unproven. Don't submit it. It will deny.

Allogeneic HCT for any testicular cancer indication. Aetna considers all allogeneic hematopoietic cell transplantation for testicular cancer experimental and unproven. There is no clinical scenario under this policy where allogeneic HCT is covered. If your center performs allogeneic procedures for this diagnosis, document that clearly in your financial counseling process so patients understand what Aetna will and won't pay.

The real issue here is appeal exposure. If your medical director is considering pushing an allogeneic case, loop in your compliance officer and legal counsel before submitting. Aetna's general administrative policies — not CPB 0617 — govern the appeal process for experimental denials. Your compliance officer can walk you through what that looks like for your provider agreement.

---

Coverage Indications at a Glance

---

Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025

These are the steps your billing team and revenue cycle managers need to take before December 5, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0617

Covered CPT Codes (When Selection Criteria Are Met)

These codes are covered for autologous HCT procedures and related services when the patient meets the clinical criteria in CPB 0617. Allogeneic HCT procedures — and any procedure used as first-line treatment — do not qualify.

Stem Cell and Bone Marrow Services (Autologous — CPT 38206 Series)

Chemotherapy Administration (CPT 96401 Series)

The policy data references 97 additional chemotherapy administration CPT codes beyond those listed above. Review the full CPB 0617 policy text at Aetna's clinical policy portal for the complete list.

Not Covered / Experimental Procedures

Exclusions under CPB 0617 are defined by indication, not by a distinct code. Allogeneic HCT for any testicular cancer indication and autologous HCT used as first-line treatment are excluded — no specific CPT codes are assigned to these exclusions in the policy.

Key ICD-10-CM Diagnosis Codes

The policy data references 94 ICD-10-CM codes tied to testicular cancer diagnoses. The complete code list is available in the full CPB 0617 policy document. Work with your coding team to confirm all testicular cancer diagnosis codes your center uses are included in Aetna's covered list before submitting claims after the December 5, 2025 effective date.

---